Keyphrases
Percutaneous Coronary Intervention
93%
Erectile Dysfunction
78%
Bifurcation Lesion
53%
Single Center
52%
Peripheral Arterial Disease
44%
Optical Coherence Tomography
39%
Sexual Dysfunction
33%
Orbital Atherectomy
32%
Cardiovascular Disease
30%
In-stent Restenosis
30%
High Risk
30%
Directional Atherectomy
28%
Side Branch
28%
High-sensitivity C-reactive Protein (hs-CRP)
28%
Phosphodiesterase Type 5 Inhibitors
28%
Drug-eluting Stent
26%
Target Lesion Revascularization
25%
Heart Failure
24%
Clinical Outcomes
22%
Chronic Heart Failure
21%
Patient Demographics
20%
Angiography
20%
Myocardial Infarction
19%
Target Lesion
19%
Severe Calcification
19%
Femoropopliteal
19%
Atherectomy
19%
Body Mass Index
18%
Moderate to Severe
18%
Confidence Interval
18%
1-year Outcome
17%
Critical Limb Ischemia
17%
Stable Coronary Artery Disease
17%
Popliteal Artery
16%
Adverse Cardiac Events
16%
Single-center Retrospective Study
15%
Sexual Behavior
15%
Adverse Events
15%
Provisional Stenting
15%
Consecutive Patients
15%
Restenosis
14%
Bioresorbable Vascular Scaffold
14%
Prognostic Impact
14%
Aorta
14%
Pathophysiology
14%
Predictors of Restenosis
14%
Complex Coronary Lesions
14%
Clinical Practice
14%
Everolimus-eluting Stent
14%
Mid-term Outcome
14%
Medicine and Dentistry
Percutaneous Coronary Intervention
100%
Erectile Dysfunction
70%
Atherectomy
57%
Optical Coherence Tomography
55%
Stenting
45%
Arteriosclerosis Obliterans
44%
Coronary Artery Disease
43%
Drug-Eluting Stent
34%
Cardiovascular System
31%
In-Stent Restenosis
30%
Cardiovascular Disease
30%
Stenosis
28%
Heart Failure
28%
Directional Atherectomy
28%
Myocardial Infarction
26%
Angiography
25%
Target Lesion Revascularization
24%
Patient Population
20%
Isotopes of Calcium
20%
Disease
19%
Prevalence
18%
Restenosis
17%
Critical Limb Ischemia
17%
Target Lesion
16%
Major Adverse Cardiac Event
16%
Popliteal Artery
16%
Adverse Event
15%
Retrospective Study
15%
Percutaneous Transluminal Angioplasty
14%
Coronary Atherectomy
14%
Ischemia
14%
Everolimus
14%
Limb
14%
Fractional Flow Reserve
14%
C Reactive Protein
14%
Amputation
14%
Injury
14%
Intravascular Ultrasound
14%
Nitinol
14%
Low Density Lipoprotein Cholesterol
14%
Statin
14%
Hemoglobin A1c
14%
Pathophysiology
14%
Phosphodiesterase V
14%
COVID-19
14%
Venous Thromboembolism
14%
Cardiovascular Risk
14%
Deep Vein Thrombosis
14%
Phosphodiesterase V Inhibitor
14%
Sildenafil
14%
Pharmacology, Toxicology and Pharmaceutical Science
Erectile Dysfunction
63%
Heart Infarction
47%
Heart Failure
42%
Adverse Event
32%
Cardiovascular Disease
30%
Prevalence
29%
Phosphodiesterase V Inhibitor
28%
Major Adverse Cardiac Event
27%
Coronary Artery Disease
25%
Sildenafil
21%
Phosphodiesterase V
17%
Stent Thrombosis
14%
Pathophysiology
14%
Everolimus
14%
C Reactive Protein
14%
Bleeding
14%
Peripheral Occlusive Artery Disease
14%
Pandemic
14%
Venous Thromboembolism
14%
Deep Vein Thrombosis
14%
Adverse Outcome
13%
Pulmonary Hypertension
12%
Vardenafil
8%
Tadalafil
8%
Retrospective Study
7%
Endothelial Dysfunction
7%
Prospective Study
7%
Coronary Artery Calcification
7%
Cause of Death
7%
Lung Embolism
5%
Obesity
5%